Building disease awareness across 11 European countries

How to engage thousands of doctors on a rare disease

Overview

We were recently tasked with the challenge of educating specialists on a rare hematology condition. Through close collaboration with key opinion leaders (KOLs), we developed a 10 minute disease awareness video, localized it into 11 languages and shared it to our hematologists and GPs. This case study highlights how we successfully bridged knowledge gaps, improved access to care for people with rare diseases, and enabled healthcare providers to make a real difference in managing acquired aplastic anemia.

Objectives

 Our main objective was to increase the knowledge of:
1 Hematologists in the diagnosis and management of this rare disease, which affects 2–6 new patients per million population annually.
2 Primary care physicians about this disease to help determine the clinical signs and laboratory parameters that should influence the decision to refer the patient to an expert center for definitive diagnosis and treatment.

Target audience

General practitioners, hematologists, and internal medicine specialists across 11 European countries.

Campaign strategy and timeline

CME educational video with a KOL from May 2024 until May 2025.

Performance

10.200 doctors educated 
in just 3 months
130 hours
of content watched in 3 months
Italy leads the way
Of the total participants, nearly half of them were from Italy, highlighting the significant interest and engagement in this particular market.

Conclusion

Our campaign successfully addressed the challenges of limited scientific knowledge and delayed diagnosis in rare diseases, educating over 10,200 medical professionals across 11 countries in just three months. With short-form educational content, we generated over 130 hours of viewing time, watched by thousands of doctors across Europe. Italy leads in engagement, and watch time continues to grow. While medical knowledge often can't be packaged into easily consumable social media videos, it can be made more interesting. And the more niche the topic, the harder we have to try if we want to meaningfully impact the lives of patients with rare diseases.